SV2010003704A - Polipeptidos modificados del factor ix y usos de los mismos - Google Patents
Polipeptidos modificados del factor ix y usos de los mismosInfo
- Publication number
- SV2010003704A SV2010003704A SV2010003704A SV2010003704A SV2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A SV 2010003704 A SV2010003704 A SV 2010003704A
- Authority
- SV
- El Salvador
- Prior art keywords
- factor
- modified
- polipeptides
- same
- polypeptides
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12456708P | 2008-04-16 | 2008-04-16 | |
| US4596108P | 2008-04-17 | 2008-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2010003704A true SV2010003704A (es) | 2011-02-21 |
Family
ID=41265284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2010003704A SV2010003704A (es) | 2008-04-16 | 2010-10-15 | Polipeptidos modificados del factor ix y usos de los mismos |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2288622A4 (fr) |
| JP (1) | JP2011517951A (fr) |
| KR (1) | KR20110005862A (fr) |
| CN (1) | CN102083856A (fr) |
| AU (1) | AU2009244633A1 (fr) |
| BR (1) | BRPI0910702A2 (fr) |
| CA (1) | CA2721683A1 (fr) |
| CO (1) | CO6311000A2 (fr) |
| CR (1) | CR11737A (fr) |
| DO (1) | DOP2010000311A (fr) |
| EC (1) | ECSP10010551A (fr) |
| IL (1) | IL208718A0 (fr) |
| MX (1) | MX2010011345A (fr) |
| RU (1) | RU2010146387A (fr) |
| SG (1) | SG189790A1 (fr) |
| SV (1) | SV2010003704A (fr) |
| WO (1) | WO2009137254A2 (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2423305A1 (fr) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Polypeptides du facteur IX à coagulation modifiée et leur utilisation pour le traitement |
| CN102026653B (zh) * | 2007-10-15 | 2014-06-18 | 北卡罗来纳-查佩尔山大学 | 半衰期延长的人因子ⅸ变体 |
| ES2985035T3 (es) | 2008-09-15 | 2024-11-04 | Uniqure Biopharma B V | Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción |
| ES3050283T3 (en) | 2010-07-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| AU2013204511B2 (en) * | 2010-11-03 | 2016-03-17 | Gc Biopharma Corp. | Modified factor ix polypeptides and uses thereof |
| HUE043894T2 (hu) | 2011-06-10 | 2019-09-30 | Bioverativ Therapeutics Inc | Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei |
| EP2737311B1 (fr) | 2011-07-25 | 2020-12-02 | Bioverativ Therapeutics Inc. | Dosages pour la surveillance de troubles hémostatiques |
| US9738884B2 (en) | 2012-04-27 | 2017-08-22 | Nihon University | Therapeutic agent for epithelial and endothelial injury |
| EP3970738A1 (fr) | 2012-07-25 | 2022-03-23 | Bioverativ Therapeutics Inc. | Essai de surveillance de facteur sanguin et utilisations de celui-ci |
| EP3542861A1 (fr) | 2012-09-25 | 2019-09-25 | Bioverativ Therapeutics Inc. | Procédés d'utilisation de polypeptides fix |
| EP2908847B1 (fr) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Procédés d'utilisation d'une dose fixe d'un facteur de coagulation |
| US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
| ES2959747T3 (es) | 2013-02-15 | 2024-02-28 | Bioverativ Therapeutics Inc | Gen del factor VIII optimizado |
| UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
| EP3048899B1 (fr) | 2013-09-25 | 2021-09-08 | Bioverativ Therapeutics Inc. | Procédés d'inactivation de virus sur colonne |
| EP3065769A4 (fr) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Composé de fusion procoagulant |
| US10325687B2 (en) | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| EP3083933A1 (fr) | 2013-12-20 | 2016-10-26 | Biogen MA Inc. | Utilisation de cultures de semences sous perfusion pour améliorer la capacité de production en alimentation programmée de produits biopharmaceutiques et la qualité des produits |
| SG10201913735SA (en) | 2014-03-24 | 2020-03-30 | Bioverativ Therapeutics Inc | Lyophilized factor ix formulations |
| WO2016004113A1 (fr) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Gène du facteur ix optimisé |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| CA2994547A1 (fr) | 2015-08-03 | 2017-02-09 | Bioverativ Therapeutics Inc. | Proteines de fusion du facteur xi et leurs methodes de production et d'utilisation |
| EP3411478B1 (fr) | 2016-02-01 | 2022-06-08 | Bioverativ Therapeutics Inc. | Gènes du facteur viii optimisés |
| CN105695616A (zh) * | 2016-04-22 | 2016-06-22 | 王冬国 | 诊断甲状腺癌的分析标志物及其应用 |
| WO2018102743A1 (fr) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques |
| CA3051862A1 (fr) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Proteine de fusion du facteur ix et procedes de fabrication et d'utilisation associes |
| FR3069540B1 (fr) | 2017-07-28 | 2019-09-13 | Universite Claude Bernard Lyon 1 | Proteine modifiee avec demi-vie amelioree |
| MY203184A (en) | 2017-08-09 | 2024-06-13 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| CA3077380A1 (fr) | 2017-09-27 | 2019-04-04 | Sigilon Therapeutics, Inc. | Procedes, compositions et elements implantables comprenant des cellules actives |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| UY38160A (es) | 2018-04-04 | 2019-11-29 | Sigilon Therapeutics Inc | Partículas implantables y métodos relacionados |
| US20210145889A1 (en) | 2018-04-04 | 2021-05-20 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| MX2021001599A (es) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y sus usos para la terapia genica no viral. |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| UY38389A (es) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | Dispositivos implantables para terapia celular y métodos relacionados |
| WO2020086408A1 (fr) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bioprocédé d'expression génique transitoire basé sur une perfusion à haut rendement |
| KR20220009389A (ko) | 2019-04-17 | 2022-01-24 | 코디악 바이오사이언시즈, 인크. | 엑소좀 및 aav 의 조성물 |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| WO2021154414A2 (fr) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| WO2022182869A1 (fr) | 2021-02-24 | 2022-09-01 | Bluehalo Llc | Système et procédé d'alimentation de réseau à commande de phase à formation de faisceau numérique |
| EP4602154A1 (fr) | 2022-10-11 | 2025-08-20 | Sigilon Therapeutics, Inc. | Cellules modifiées et éléments implantables pour le traitement d'une maladie |
| WO2024081309A1 (fr) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Cellules modifiées et éléments implantables pour le traitement d'une maladie |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2638643B1 (fr) * | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
| WO1999003496A1 (fr) * | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Facteur ix antihemophilique presentant une activite de coagulation augmentee |
| RU2004110239A (ru) * | 2001-09-04 | 2005-10-20 | Мерк Патент ГмбХ (DE) | Модифицированный фактор ix |
| CA2520970A1 (fr) * | 2003-04-09 | 2004-10-28 | Robert G. Schaub | Traitement de l'hemophilie par inhalation de facteurs de coagulation |
| AU2004296860B2 (en) * | 2003-12-03 | 2010-04-22 | Novo Nordisk A/S | Glycopegylated factor IX |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP2423305A1 (fr) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Polypeptides du facteur IX à coagulation modifiée et leur utilisation pour le traitement |
| US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2009
- 2009-04-16 CN CN2009801227842A patent/CN102083856A/zh active Pending
- 2009-04-16 BR BRPI0910702A patent/BRPI0910702A2/pt not_active IP Right Cessation
- 2009-04-16 SG SG2013028790A patent/SG189790A1/en unknown
- 2009-04-16 CA CA2721683A patent/CA2721683A1/fr not_active Abandoned
- 2009-04-16 WO PCT/US2009/040813 patent/WO2009137254A2/fr not_active Ceased
- 2009-04-16 KR KR1020107025567A patent/KR20110005862A/ko not_active Ceased
- 2009-04-16 RU RU2010146387/10A patent/RU2010146387A/ru not_active Application Discontinuation
- 2009-04-16 EP EP09743241A patent/EP2288622A4/fr not_active Withdrawn
- 2009-04-16 MX MX2010011345A patent/MX2010011345A/es not_active Application Discontinuation
- 2009-04-16 AU AU2009244633A patent/AU2009244633A1/en not_active Abandoned
- 2009-04-16 JP JP2011505204A patent/JP2011517951A/ja active Pending
-
2010
- 2010-10-14 IL IL208718A patent/IL208718A0/en unknown
- 2010-10-15 CO CO10128682A patent/CO6311000A2/es active IP Right Grant
- 2010-10-15 EC EC2010010551A patent/ECSP10010551A/es unknown
- 2010-10-15 CR CR11737A patent/CR11737A/es not_active Application Discontinuation
- 2010-10-15 DO DO2010000311A patent/DOP2010000311A/es unknown
- 2010-10-15 SV SV2010003704A patent/SV2010003704A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009137254A3 (fr) | 2010-01-14 |
| CR11737A (es) | 2011-02-07 |
| CN102083856A (zh) | 2011-06-01 |
| IL208718A0 (en) | 2010-12-30 |
| CA2721683A1 (fr) | 2009-11-12 |
| DOP2010000311A (es) | 2011-02-28 |
| WO2009137254A2 (fr) | 2009-11-12 |
| EP2288622A4 (fr) | 2012-04-18 |
| AU2009244633A1 (en) | 2009-11-12 |
| BRPI0910702A2 (pt) | 2016-07-05 |
| RU2010146387A (ru) | 2012-05-27 |
| ECSP10010551A (es) | 2010-11-30 |
| MX2010011345A (es) | 2011-02-23 |
| KR20110005862A (ko) | 2011-01-19 |
| JP2011517951A (ja) | 2011-06-23 |
| SG189790A1 (en) | 2013-05-31 |
| EP2288622A2 (fr) | 2011-03-02 |
| CO6311000A2 (es) | 2011-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2010003704A (es) | Polipeptidos modificados del factor ix y usos de los mismos | |
| DOP2012000030A (es) | Polipéptidos del factor ix modificados y usos de los mismos | |
| SV2009003393A (es) | Polipeptidos de factor vii modificaciones y usos de los mismos | |
| CR20140512A (es) | Dispositivos y metodos para la fabricación de aditivos de componentes de implante | |
| CO6331368A2 (es) | Factores modificados de polipeptidos vii (fvii) | |
| ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
| UY34781A (es) | Moduladores de la via del complemento y usos de los mismos | |
| CL2011002700A1 (es) | Marcador de eventos ingerible altamente confiable y metodo para el uso del mismo. | |
| ECSP12012024A (es) | Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados | |
| CL2008001626A1 (es) | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. | |
| BR112013010834B1 (pt) | polipeptídeos de fator ix modificados e usos dos mesmos | |
| CL2020000019A1 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso. | |
| CR20110630A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína | |
| NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| DOP2010000251A (es) | Paramyxovirus eficaz como antitumoral | |
| DOP2010000346A (es) | Sal de difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi}quinazolina | |
| UY29250A1 (es) | Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.- | |
| BR112014028443A8 (pt) | Composição estéril esterilizada com radiação | |
| PA8824601A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia | |
| UY32975A (es) | Derivados de aminopiridina | |
| CR11457A (es) | Composiciones farmaceuticas que contienen antagonistas de bradykinin y acido hialuronico y los usos de los mismos | |
| MX2016005227A (es) | Polipéptidos de acción prolongada y métodos para su producción y administración. | |
| ATE544422T1 (de) | Chirurgisches netz | |
| Dixon | EPPM-2 conference report: The 2nd Conference of the European Platform for Photodynamic Medicine (EPPM) in conjunction with the 13th Bi Annual Congress of the European Society for Photobiology (ESP), 5th-10th September 2009, Wroclaw | |
| AR112754A1 (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO |